{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:09:25Z","timestamp":1792804165865,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>MRTX1133 is a first-in-class KRAS G12D inhibitor being in phase I\/II clinical trials. KRAS is the most frequently mutated oncogene in pancreatic ductal adenocarcinoma (PDAC), with a predominance of the G12D variant. PDAC is a highly lethal cancer type with an extremely low 5-year survival rate. Although PDAC metastasis most frequently targets the liver, the influence of MRTX1133 treatment on hepatic metastases has not yet been investigated thoroughly. Thus, we aimed to analyze the effect of MRTX1133 treatment on local tumor growth and liver metastasis development. Cell proliferation and migration were investigated in vitro using clonogenic, scratch, Boyden chamber, and immunoblot assay in three KRAS G12D mutated PDAC cell lines (ASPC1, SW1990, PANC1). Moreover, PANC1 was examined in vivo in a spleen-to-liver metastatic xenograft model using NXG female mice. The MRTX1133 treatment decreased clonogenic proliferation and migratory activity; furthermore, it inhibited both local tumor growth in the spleen and liver colonization. MRTX1133 induced alterations associated with mesenchymal-to-epithelial transition; furthermore, lower levels of activated Erk, altered FAK expression, and activation were observed. In addition to the antiproliferative effects of MRTX1133, our in vitro and in vivo results indicate the importance of MRTX1133 as a potential antimetastatic drug in PDAC therapy.<\/jats:p>","DOI":"10.1038\/s41598-025-34204-y","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:37:43Z","timestamp":1767789463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antimetastatic effects of MRTX1133 KRAS G12D specific inhibitor in a liver metastatic model of pancreatic ductal adenocarcinoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Krisztina Andrea","family":"Szigeti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcell","family":"Baranyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ra","family":"Surguta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Heged\u0171s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violetta","family":"Piurk\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef","family":"T\u00f3v\u00e1ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef","family":"T\u00edm\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"34204_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"34204_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"34204_CR3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/S1542-3565(04)00171-5","volume":"2","author":"EA Holly","year":"2004","unstructured":"Holly, E. A., Chaliha, I., Bracci, P. M. & Gautam, M. Signs and symptoms of pancreatic cancer: A population-based case-control study in the San Francisco Bay area. Clin. Gastroenterol. Hepatol. 2, 510\u2013517 (2004).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"34204_CR4","doi-asserted-by":"publisher","first-page":"931","DOI":"10.5858\/2008-132-931-MPOCRF","volume":"132","author":"G Disibio","year":"2008","unstructured":"Disibio, G. & French, S. W. Metastatic patterns of cancers: Results from a large autopsy study. Arch. Pathol. Lab. Med. 132, 931\u2013939 (2008).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"34204_CR5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.4161\/cbt.4.5.1663","volume":"4","author":"EE Embuscado","year":"2005","unstructured":"Embuscado, E. E. et al. Immortalizing the complexity of cancer metastasis: Genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol. Ther. 4, 548\u2013554 (2005).","journal-title":"Cancer Biol. Ther."},{"key":"34204_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/00006676-199511000-00005","volume":"11","author":"T Kamisawa","year":"1995","unstructured":"Kamisawa, T., Isawa, T., Koike, M., Tsuruta, K. & Okamoto, A. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas 11, 345\u2013349 (1995).","journal-title":"Pancreas"},{"key":"34204_CR7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot, V. P. et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann. Surg. 267, 936\u2013945 (2018).","journal-title":"Ann. Surg."},{"key":"34204_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.path.2016.05.003","volume":"9","author":"C Luchini","year":"2016","unstructured":"Luchini, C., Capelli, P. & Scarpa, A. Pancreatic ductal adenocarcinoma and its variants. Surg. Pathol. Clin. 9, 547\u2013560 (2016).","journal-title":"Surg. Pathol. Clin."},{"key":"34204_CR9","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41401-020-00584-2","volume":"42","author":"H-F Hu","year":"2021","unstructured":"Hu, H.-F. et al. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacol. Sin. 42, 1725\u20131741 (2021).","journal-title":"Acta Pharmacol. Sin."},{"key":"34204_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.216","volume":"4","author":"H-C Kung","year":"2023","unstructured":"Kung, H.-C. & Yu, J. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. MedComm 4, e216 (2023).","journal-title":"MedComm"},{"key":"34204_CR11","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"34204_CR12","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"34204_CR13","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial. Lancet 402, 1272\u20131281 (2023).","journal-title":"Lancet"},{"key":"34204_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-023-02935-3","volume":"43","author":"W Luo","year":"2024","unstructured":"Luo, W., Wen, T. & Qu, X. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept. J. Exp. Clin. Cancer Res. 43, 8 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"34204_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216636","volume":"585","author":"H Wei","year":"2024","unstructured":"Wei, H. & Ren, H. Precision treatment of pancreatic ductal adenocarcinoma. Cancer Lett. 585, 216636 (2024).","journal-title":"Cancer Lett."},{"key":"34204_CR16","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M. & Maitra, A. Pancreatic cancer: Advances and challenges. Cell 186, 1729\u20131754 (2023).","journal-title":"Cell"},{"key":"34204_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216391","volume":"574","author":"O Li","year":"2023","unstructured":"Li, O. et al. Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular. Cancer Lett. 574, 216391 (2023).","journal-title":"Cancer Lett."},{"key":"34204_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","volume":"17","author":"L Buscail","year":"2020","unstructured":"Buscail, L., Bournet, B. & Cordelier, P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 153\u2013168 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"34204_CR19","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1038\/s41467-018-04449-5","volume":"9","author":"H Shibata","year":"2018","unstructured":"Shibata, H. et al. In vivo reprogramming drives Kras-induced cancer development. Nat. Commun. 9, 2081 (2018).","journal-title":"Nat. Commun."},{"key":"34204_CR20","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548\u2013551 (2013).","journal-title":"Nature"},{"key":"34204_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","volume":"6","author":"MP Patricelli","year":"2016","unstructured":"Patricelli, M. P. et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6, 316\u2013329 (2016).","journal-title":"Cancer Discov."},{"key":"34204_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"34204_CR23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","volume":"172","author":"MR Janes","year":"2018","unstructured":"Janes, M. R. et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172, 578-589.e17 (2018).","journal-title":"Cell"},{"key":"34204_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin, J. et al. The KRAS inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54\u201371 (2020).","journal-title":"Cancer Discov."},{"key":"34204_CR25","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/oncolo\/oyab080","volume":"27","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Phase I study of JNJ-74699157 in patients with advanced solid tumors harboring the KRAS G12C mutation. Oncologist 27, 536-e553 (2022).","journal-title":"Oncologist"},{"key":"34204_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41421-021-00368-w","volume":"8","author":"Z Mao","year":"2022","unstructured":"Mao, Z. et al. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discov. 8, 5 (2022).","journal-title":"Cell Discov."},{"key":"34204_CR27","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41416-024-02586-x","volume":"130","author":"M Baranyi","year":"2024","unstructured":"Baranyi, M. et al. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors. Br. J. Cancer 130, 1059\u20131072 (2024).","journal-title":"Br. J. Cancer"},{"key":"34204_CR28","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin, J. et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS inhibitor. Nat. Med. 28, 2171\u20132182 (2022).","journal-title":"Nat. Med."},{"key":"34204_CR29","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS Inhibitor. J. Med. Chem. 65, 3123\u20133133 (2022).","journal-title":"J. Med. Chem."},{"key":"34204_CR30","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457\u20132467 (2012).","journal-title":"Cancer Res."},{"key":"34204_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"BJ Raphael","year":"2017","unstructured":"Raphael, B. J. et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185-203.e13 (2017).","journal-title":"Cancer Cell"},{"key":"34204_CR32","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","volume":"39","author":"J Timar","year":"2020","unstructured":"Timar, J. & Kashofer, K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 39, 1029\u20131038 (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"34204_CR33","doi-asserted-by":"publisher","first-page":"1013902","DOI":"10.3389\/fonc.2022.1013902","volume":"12","author":"SF Bannoura","year":"2022","unstructured":"Bannoura, S. F., Khan, H. Y. & Azmi, A. S. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?. Front. Oncol. 12, 1013902 (2022).","journal-title":"Front. Oncol."},{"key":"34204_CR34","doi-asserted-by":"publisher","first-page":"799","DOI":"10.32604\/or.2024.045356","volume":"32","author":"S Stickler","year":"2024","unstructured":"Stickler, S., Rath, B. & Hamilton, G. Targeting KRAS in pancreatic cancer. Oncol. Res. 32, 799\u2013805 (2024).","journal-title":"Oncol. Res."},{"key":"34204_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.151688","volume":"760","author":"R Kale","year":"2025","unstructured":"Kale, R., Samant, C., Nandakumar, K., Ranganath Pai, K. S. & Bhonde, M. Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors. Biochem. Biophys. Res. Commun. 760, 151688 (2025).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"34204_CR36","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-23-1313","volume":"83","author":"KCM Gulay","year":"2023","unstructured":"Gulay, K. C. M. et al. Dual Inhibition of KRASG12D and Pan-ERBB is synergistic in pancreatic ductal adenocarcinoma. Cancer Res. 83, 3001\u20133012 (2023).","journal-title":"Cancer Res."},{"key":"34204_CR37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","volume":"13","author":"SB Kemp","year":"2023","unstructured":"Kemp, S. B. et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 13, 298\u2013311 (2023).","journal-title":"Cancer Discov."},{"key":"34204_CR38","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan, K. K. et al. KRAS inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8 T cells. Cancer Cell 41, 1606-1620.e8 (2023).","journal-title":"Cancer Cell"},{"key":"34204_CR39","doi-asserted-by":"publisher","first-page":"1611948","DOI":"10.3389\/pore.2024.1611948","volume":"30","author":"E Moln\u00e1r","year":"2024","unstructured":"Moln\u00e1r, E. et al. Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer. Pathol. Oncol. Res. 30, 1611948 (2024).","journal-title":"Pathol. Oncol. Res."},{"key":"34204_CR40","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly, J. et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 14, 2135\u20132161 (2024).","journal-title":"Cancer Discov."},{"key":"34204_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0344-0338(83)80043-0","volume":"177","author":"J Tim\u00e1r","year":"1983","unstructured":"Tim\u00e1r, J., Kopper, L., P\u00e1l, K. & Lapis, K. Transmission and scanning-electronmicroscopy of experimental liver metastases derived from intrasplenically growing primary tumor. Pathol. Res. Pract. 177, 47\u201359 (1983).","journal-title":"Pathol. Res. Pract."},{"key":"34204_CR42","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41388-023-02676-9","volume":"42","author":"J Feng","year":"2023","unstructured":"Feng, J. et al. Feedback activation of EGFR\/wild-type RAS signaling axis limits KRAS inhibitor efficacy in KRAS-mutated colorectal cancer. Oncogene 42, 1620\u20131633 (2023).","journal-title":"Oncogene"},{"key":"34204_CR43","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ccell.2021.02.009","volume":"39","author":"A Singh","year":"2021","unstructured":"Singh, A. et al. A gene expression signature associated with K-Ras addiction reveals regulators of EMT and tumor cell survival. Cancer Cell 39, 441\u2013442 (2021).","journal-title":"Cancer Cell"},{"key":"34204_CR44","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1158\/1078-0432.CCR-18-0368","volume":"25","author":"S Misale","year":"2019","unstructured":"Misale, S. et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin. Cancer Res. 25, 796\u2013807 (2019).","journal-title":"Clin. Cancer Res."},{"key":"34204_CR45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrc.2016.25","volume":"16","author":"PS Steeg","year":"2016","unstructured":"Steeg, P. S. Targeting metastasis. Nat. Rev. Cancer 16, 201\u2013218 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"34204_CR46","doi-asserted-by":"publisher","first-page":"480","DOI":"10.21037\/gs-23-465","volume":"13","author":"H Zhang","year":"2024","unstructured":"Zhang, H., Tan, Q., Xiang, C., Liu, X. & Zheng, Z. Increased risk of multiple metastases and worse overall survival of metastatic pancreatic body and tail cancer: A retrospective cohort study. Gland Surg. 13, 480\u2013489 (2024).","journal-title":"Gland Surg."},{"key":"34204_CR47","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1101\/gad.293449.116","volume":"31","author":"AT Boutin","year":"2017","unstructured":"Boutin, A. T. et al. Oncogenic drives invasion and maintains metastases in colorectal cancer. Genes Dev. 31, 370\u2013382 (2017).","journal-title":"Genes Dev."},{"key":"34204_CR48","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1038\/onc.2014.416","volume":"34","author":"E Lemieux","year":"2015","unstructured":"Lemieux, E., Cagnol, S., Beaudry, K., Carrier, J. & Rivard, N. Oncogenic KRAS signalling promotes the Wnt\/\u03b2-catenin pathway through LRP6 in colorectal cancer. Oncogene 34, 4914\u20134927 (2015).","journal-title":"Oncogene"},{"key":"34204_CR49","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1007\/s00268-019-05158-w","volume":"43","author":"T-C Kuan","year":"2019","unstructured":"Kuan, T.-C. et al. Prognosticators of long-term outcomes of TNM Stage II colorectal cancer: Molecular patterns or clinicopathological features. World J. Surg. 43, 3207\u20133215 (2019).","journal-title":"World J. Surg."},{"key":"34204_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239806","volume":"15","author":"P Jo","year":"2020","unstructured":"Jo, P. et al. KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer. PLoS ONE 15, e0239806 (2020).","journal-title":"PLoS ONE"},{"key":"34204_CR51","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/jso.23675","volume":"110","author":"C-C Lin","year":"2014","unstructured":"Lin, C.-C. et al. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer. J. Surg. Oncol. 110, 451\u2013457 (2014).","journal-title":"J. Surg. Oncol."},{"key":"34204_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111717","volume":"140","author":"M Meng","year":"2021","unstructured":"Meng, M. et al. The current understanding on the impact of KRAS on colorectal cancer. Biomed. Pharmacother. 140, 111717 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"34204_CR53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00595-024-02900-3","volume":"55","author":"K Chen","year":"2024","unstructured":"Chen, K. et al. The KRAS G12D mutation increases the risk of unresectable recurrence of resectable colorectal liver-only metastasis. Surg. Today 55, 273\u2013282 (2024).","journal-title":"Surg. Today"},{"key":"34204_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35428","volume":"10","author":"G Yao","year":"2024","unstructured":"Yao, G. et al. Comparative analysis of the mutational landscape and evolutionary patterns of pancreatic ductal adenocarcinoma metastases in the liver or peritoneum. Heliyon 10, e35428 (2024).","journal-title":"Heliyon"},{"key":"34204_CR55","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/2767-9764.CRC-21-0100","volume":"2","author":"L Silwal-Pandit","year":"2022","unstructured":"Silwal-Pandit, L. et al. Proteome analysis of pancreatic tumors implicates extracellular matrix in patient outcome. Cancer Res. Commun. 2, 434\u2013446 (2022).","journal-title":"Cancer Res. Commun."},{"key":"34204_CR56","doi-asserted-by":"crossref","unstructured":"Pan, H. et al. DYRK2 regulates epithelial-mesenchymal transition restriction in pancreatic cancer liver metastasis by inhibiting Twist. Digestion 1\u201318 (2024).","DOI":"10.1159\/000541039"},{"key":"34204_CR57","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41417-024-00864-7","volume":"32","author":"R Li","year":"2024","unstructured":"Li, R. et al. ITGA3 promotes pancreatic cancer progression through HIF1\u03b1- and c-Myc-driven glycolysis in a collagen I-dependent autocrine manner. Cancer Gene Ther. 32, 240\u2013253 (2024).","journal-title":"Cancer Gene Ther."},{"key":"34204_CR58","doi-asserted-by":"publisher","first-page":"1347683","DOI":"10.3389\/fimmu.2024.1347683","volume":"15","author":"H Yang","year":"2024","unstructured":"Yang, H. et al. Molecular mechanisms of pancreatic cancer liver metastasis: The role of PAK2. Front. Immunol. 15, 1347683 (2024).","journal-title":"Front. Immunol."},{"key":"34204_CR59","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1186\/s12885-022-09577-2","volume":"22","author":"H Luan","year":"2022","unstructured":"Luan, H., He, Y., Zhang, T., Su, Y. & Zhou, L. The identification of liver metastasis- and prognosis-associated genes in pancreatic ductal adenocarcinoma. BMC Cancer 22, 463 (2022).","journal-title":"BMC Cancer"},{"key":"34204_CR60","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1038\/s41591-024-03075-7","volume":"30","author":"L Bojmar","year":"2024","unstructured":"Bojmar, L. et al. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Nat. Med. 30, 2170\u20132180 (2024).","journal-title":"Nat. Med."},{"key":"34204_CR61","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s43018-024-00731-2","volume":"5","author":"Y Astuti","year":"2024","unstructured":"Astuti, Y. et al. Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis. Nat. Cancer 5, 774\u2013790 (2024).","journal-title":"Nat. Cancer"},{"key":"34204_CR62","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/0008-5472.CAN-23-2504","volume":"84","author":"V Kumarasamy","year":"2024","unstructured":"Kumarasamy, V. et al. The extracellular niche and tumor microenvironment enhance KRAS inhibitor efficacy in pancreatic cancer. Cancer Res. 84, 1115\u20131132 (2024).","journal-title":"Cancer Res."},{"key":"34204_CR63","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.trsl.2024.05.003","volume":"271","author":"M Huerta","year":"2024","unstructured":"Huerta, M. et al. ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients. Trans. Res. 271, 105\u2013115 (2024).","journal-title":"Trans. Res."},{"key":"34204_CR64","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1158\/1078-0432.CCR-06-0456","volume":"12","author":"PMF Siesser","year":"2006","unstructured":"Siesser, P. M. F. & Hanks, S. K. The signaling and biological implications of FAK overexpression in cancer. Clin. Cancer Res. 12, 3233\u20133237 (2006).","journal-title":"Clin. Cancer Res."},{"key":"34204_CR65","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1242\/jcs.02565","volume":"118","author":"A Hamadi","year":"2005","unstructured":"Hamadi, A. et al. Regulation of focal adhesion dynamics and disassembly by phosphorylation of FAK at tyrosine 397. J. Cell Sci. 118, 4415\u20134425 (2005).","journal-title":"J. Cell Sci."},{"key":"34204_CR66","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/cells9010192","volume":"9","author":"K Katoh","year":"2020","unstructured":"Katoh, K. FAK-dependent cell motility and cell elongation. Cells 9, 192 (2020).","journal-title":"Cells"},{"key":"34204_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.998475","volume":"9","author":"SC Samson","year":"2022","unstructured":"Samson, S. C., Khan, A. M. & Mendoza, M. C. ERK signaling for cell migration and invasion. Front. Mol. Biosci. 9, 998475 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"34204_CR68","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/jb\/mvx048","volume":"162","author":"S Tanimura","year":"2017","unstructured":"Tanimura, S. & Takeda, K. ERK signalling as a regulator of cell motility. J. Biochem. 162, 145\u2013154 (2017).","journal-title":"J. Biochem."},{"key":"34204_CR69","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/1878-0261.13732","volume":"19","author":"D de la Fuente-Vivas","year":"2024","unstructured":"de la Fuente-Vivas, D. et al. ERK1\/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility. Mol. Oncol. 19, 452\u2013473 (2024).","journal-title":"Mol. Oncol."},{"key":"34204_CR70","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1083\/jcb.113.1.173","volume":"113","author":"UH Frixen","year":"1991","unstructured":"Frixen, U. H. et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol. 113, 173\u2013185 (1991).","journal-title":"J. Cell Biol."},{"key":"34204_CR71","first-page":"75","volume":"1796","author":"A Voulgari","year":"2009","unstructured":"Voulgari, A. & Pintzas, A. Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 1796, 75\u201390 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"34204_CR72","first-page":"483","volume":"150","author":"MJ Hendrix","year":"1997","unstructured":"Hendrix, M. J., Seftor, E. A., Seftor, R. E. & Trevor, K. T. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am. J. Pathol. 150, 483\u2013495 (1997).","journal-title":"Am. J. Pathol."},{"issue":"Pt 24","key":"34204_CR73","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1242\/jcs.112.24.4615","volume":"112","author":"C Gilles","year":"1999","unstructured":"Gilles, C. et al. Vimentin contributes to human mammary epithelial cell migration. J. Cell Sci. 112(Pt 24), 4615\u20134625 (1999).","journal-title":"J. Cell Sci."},{"key":"34204_CR74","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1038\/onc.2008.343","volume":"27","author":"A Jeanes","year":"2008","unstructured":"Jeanes, A., Gottardi, C. J. & Yap, A. S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression?. Oncogene 27, 6920\u20136929 (2008).","journal-title":"Oncogene"},{"key":"34204_CR75","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1073\/pnas.87.11.4246","volume":"87","author":"M Ozawa","year":"1990","unstructured":"Ozawa, M., Ringwald, M. & Kemler, R. Uvomorulin-catenin complex formation is regulated by a specific domain in the cytoplasmic region of the cell adhesion molecule. Proc. Natl. Acad. Sci. U. S. A. 87, 4246\u20134250 (1990).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"34204_CR76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0896-6273(02)00764-X","volume":"35","author":"S Murase","year":"2002","unstructured":"Murase, S., Mosser, E. & Schuman, E. M. Depolarization drives beta-Catenin into neuronal spines promoting changes in synaptic structure and function. Neuron 35, 91\u2013105 (2002).","journal-title":"Neuron"},{"key":"34204_CR77","first-page":"303","volume":"22","author":"RL Daugherty","year":"2007","unstructured":"Daugherty, R. L. & Gottardi, C. J. Phospho-regulation of Beta-catenin adhesion and signaling functions. Physiology (Bethesda) 22, 303\u2013309 (2007).","journal-title":"Physiology (Bethesda)"},{"key":"34204_CR78","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/35000025","volume":"2","author":"A Cano","year":"2000","unstructured":"Cano, A. et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2, 76\u201383 (2000).","journal-title":"Nat. Cell Biol."},{"key":"34204_CR79","doi-asserted-by":"publisher","first-page":"8184","DOI":"10.1128\/MCB.21.23.8184-8188.2001","volume":"21","author":"EA Carver","year":"2001","unstructured":"Carver, E. A., Jiang, R., Lan, Y., Oram, K. F. & Gridley, T. The mouse snail gene encodes a key regulator of the epithelial-mesenchymal transition. Mol. Cell. Biol. 21, 8184\u20138188 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"34204_CR80","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrm757","volume":"3","author":"MA Nieto","year":"2002","unstructured":"Nieto, M. A. The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 3, 155\u2013166 (2002).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"34204_CR81","first-page":"1613","volume":"62","author":"KM Hajra","year":"2002","unstructured":"Hajra, K. M., Chen, D.Y.-S. & Fearon, E. R. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62, 1613\u20131618 (2002).","journal-title":"Cancer Res."},{"key":"34204_CR82","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","volume":"29","author":"A Bairoch","year":"2018","unstructured":"Bairoch, A. The cellosaurus, a cell-line knowledge resource. J. Biomol. Tech. 29, 25\u201338 (2018).","journal-title":"J. Biomol. Tech."},{"key":"34204_CR83","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.lungcan.2023.03.003","volume":"178","author":"L Heged\u00fcs","year":"2023","unstructured":"Heged\u00fcs, L. et al. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy. Lung Cancer 178, 237\u2013246 (2023).","journal-title":"Lung Cancer"},{"key":"34204_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232565","volume":"15","author":"A Suarez-Arnedo","year":"2020","unstructured":"Suarez-Arnedo, A. et al. An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays. PLoS ONE 15, e0232565 (2020).","journal-title":"PLoS ONE"},{"key":"34204_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087293","volume":"9","author":"A Degasperi","year":"2014","unstructured":"Degasperi, A. et al. Evaluating strategies to normalise biological replicates of Western blot data. PLoS ONE 9, e87293 (2014).","journal-title":"PLoS ONE"},{"key":"34204_CR86","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"34204_CR87","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry, S. et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv. Anat. Pathol. 24, 311\u2013335 (2017).","journal-title":"Adv. Anat. Pathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34204-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34204-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34204-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:04:34Z","timestamp":1769771074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34204-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34204"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34204-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4144"}}